Role of Novel Bispecific Antibodies and Immunotherapy in Non–Small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
- 1 October 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500023
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effectsiScience, 2024
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR VariantJAMA, 2024
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyAnnals of Oncology, 2023
- Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialAnnals of Oncology, 2023
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or BrainJournal of Thoracic Oncology, 2022
- Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJournal of Thoracic Oncology, 2021
- Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLCJournal of Thoracic Oncology, 2021
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR MutationJournal of Thoracic Oncology, 2019
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-AnalysisJournal of Thoracic Oncology, 2017
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancerScience China Life Sciences, 2016